# KCNA2

## Overview
The KCNA2 gene encodes the potassium voltage-gated channel subfamily A member 2, commonly referred to as Kv1.2, which is a crucial component of the voltage-gated potassium channel family. This protein is categorized as a transmembrane channel and plays a significant role in the regulation of neuronal excitability by facilitating the repolarization phase of action potentials in neurons. Kv1.2 channels are predominantly expressed in excitable cells, such as neurons, where they contribute to the precise timing and frequency of neuronal firing, essential for normal brain function and communication. The protein's structure allows it to form homo- or heterotetrameric complexes with other Kv1 family members, thereby diversifying its functional properties. Mutations in the KCNA2 gene have been linked to various neurological disorders, including epileptic encephalopathy and ataxia, highlighting its importance in maintaining proper neuronal function (Masnada2017Clinical; Syrbe2015De; Imbrici2021A).

## Structure
The KCNA2 gene encodes the Kv1.2 protein, a voltage-gated potassium channel that is part of the Shaker-related subfamily. The protein is composed of four alpha subunits, each containing six transmembrane segments (S1-S6) (Imbrici2021A; Corbett2016DominantKCNA2mutation). The S1-S4 segments form the voltage-sensing domain, while the S5-S6 segments form the pore domain, which includes a selectivity filter in the pore loop (Döring2021Refining; Imbrici2021A). 

The Kv1.2 channel can form homo- or heterotetramers with other Kv1 family members, allowing for diverse functional channel combinations (Masnada2017Clinical; Imbrici2021A). The protein's structure includes a PVP motif in the S6 transmembrane domain, which is crucial for channel gating and is a known mutational hotspot (Döring2021Refining). 

Kv1.2 channels are typically found in high-density clusters in neuronal regions such as the juxtaparanodal region, axonal initial segments, and presynaptic terminals, where they play a key role in regulating neuronal excitability and action potential firing patterns (Imbrici2021A; Niday2018Potassium). The protein's function can be modulated by interactions with cytoplasmic auxiliary subunits and other proteins (Imbrici2021A).

## Function
KCNA2 encodes a protein that is a component of the voltage-gated potassium channel, specifically part of the Kv1 subfamily. These channels are crucial for regulating neuronal excitability by facilitating the repolarization phase of the action potential in neurons. This process is essential for controlling electrical signaling within the nervous system, influencing activities such as neurotransmitter release and muscle contraction (Heitzmann2008Physiology; Gu2014Physiological).

The Kv1 channels, including those formed by KCNA2, are activated by depolarizing changes in membrane potential. They are primarily expressed in excitable cells, such as neurons, where they play a significant role in the rapid repolarization of the plasma membrane during action potentials. This activity is vital for maintaining the proper timing and frequency of neuronal firing, which is necessary for normal brain function and communication between neurons (Heitzmann2008Physiology).

In addition to their role in neurons, Kv1 channels are also found in nonexcitable cells, where they contribute to various cellular functions, including electrolyte transport and cell volume regulation. The proper functioning of these channels is critical for maintaining cellular homeostasis and overall physiological balance (Heitzmann2008Physiology).

## Clinical Significance
Mutations in the KCNA2 gene, which encodes a voltage-gated potassium channel, are associated with a range of neurological disorders. These include epileptic encephalopathy, characterized by severe epilepsy, developmental delays, and intellectual disabilities (Masnada2017Clinical; Syrbe2015De). The mutations can result in either loss-of-function or gain-of-function effects on the Kv1.2 channel, leading to different clinical outcomes. Loss-of-function mutations are often linked to milder phenotypes, while gain-of-function mutations are associated with more severe conditions, including ataxia and pharmacoresistant epilepsy (Masnada2017Clinical; Syrbe2015De).

Specific mutations, such as R297Q and L298F, have been identified as causing severe phenotypes, including intellectual disability and ataxia (Syrbe2015De). The clinical spectrum of KCNA2-related disorders also includes episodic ataxia and cerebellar atrophy, with some mutations showing both gain- and loss-of-function effects (Masnada2017Clinical; Corbett2016DominantKCNA2mutation). These mutations affect neuronal excitability and can lead to a variety of seizure types, developmental impairments, and motor skill deficits (Masnada2017Clinical; Imbrici2021A). The phenotypic variability underscores the complex role of KCNA2 in neurological function and disease.

## Interactions
The KCNA2 gene encodes the Kv1.2 potassium channel, which is involved in various protein-protein interactions that regulate its function and localization. Kv1.2 channels can form heterotetrameric complexes with other Kv1 family members, influencing their electrophysiological properties (Imbrici2021A). These channels interact with cytoplasmic auxiliary Kvβ subunits, such as Kvβ1 and Kvβ2, which modulate channel inactivation kinetics and are prominently associated with Kv1.2 in the brain (Rhodes1997Association).

Kv1.2 channels also interact with the amino acid transporter Slc7a5, which can modify the channel's properties by reducing its expression and altering voltage-dependent activation (Imbrici2021A). The sigma 1 receptor (Sig-1R) binds to the S2-S3 segment of Kv1.2, modulating gating modes and reducing potassium current (Imbrici2021A). Additionally, the Fragile X Mental Retardation Protein (FMRP) binds to a phosphorylated serine motif in the C-terminus of Kv1.2, regulating neuronal excitability (Imbrici2021A).

These interactions highlight the complex regulatory network involving Kv1.2 channels, which play a crucial role in neuronal excitability and are implicated in various neurological disorders, including epilepsy and ataxia (Döring2021Refining).


## References


[1. (Syrbe2015De) Steffen Syrbe, Ulrike B S Hedrich, Erik Riesch, Tania Djémié, Stephan Müller, Rikke S Møller, Bridget Maher, Laura Hernandez-Hernandez, Matthis Synofzik, Hande S Caglayan, Mutluay Arslan, José M Serratosa, Michael Nothnagel, Patrick May, Roland Krause, Heidrun Löffler, Katja Detert, Thomas Dorn, Heinrich Vogt, Günter Krämer, Ludger Schöls, Primus E Mullis, Tarja Linnankivi, Anna-Elina Lehesjoki, Katalin Sterbova, Dana C Craiu, Dorota Hoffman-Zacharska, Christian M Korff, Yvonne G Weber, Maja Steinlin, Sabina Gallati, Astrid Bertsche, Matthias K Bernhard, Andreas Merkenschlager, Wieland Kiess, Michael Gonzalez, Stephan Züchner, Aarno Palotie, Arvid Suls, Peter De Jonghe, Ingo Helbig, Saskia Biskup, Markus Wolff, Snezana Maljevic, Rebecca Schüle, Sanjay M Sisodiya, Sarah Weckhuysen, Holger Lerche, and Johannes R Lemke. De novo loss- or gain-of-function mutations in kcna2 cause epileptic encephalopathy. Nature Genetics, 47(4):393–399, March 2015. URL: http://dx.doi.org/10.1038/ng.3239, doi:10.1038/ng.3239. This article has 221 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ng.3239)

[2. (Masnada2017Clinical) Silvia Masnada, Ulrike B S Hedrich, Elena Gardella, Julian Schubert, Charu Kaiwar, Eric W Klee, Brendan C Lanpher, Ralitza H Gavrilova, Matthis Synofzik, Thomas Bast, Kathleen Gorman, Mary D King, Nicholas M Allen, Judith Conroy, Bruria Ben Zeev, Michal Tzadok, Christian Korff, Fanny Dubois, Keri Ramsey, Vinodh Narayanan, Jose M Serratosa, Beatriz G Giraldez, Ingo Helbig, Eric Marsh, Margaret O’Brien, Christina A Bergqvist, Adrian Binelli, Brenda Porter, Eduardo Zaeyen, Dafne D Horovitz, Markus Wolff, Dragan Marjanovic, Hande S Caglayan, Mutluay Arslan, Sergio D J Pena, Sanjay M Sisodiya, Simona Balestrini, Steffen Syrbe, Pierangelo Veggiotti, Johannes R Lemke, Rikke S Møller, Holger Lerche, and Guido Rubboli. Clinical spectrum and genotype–phenotype associations of kcna2-related encephalopathies. Brain, 140(9):2337–2354, August 2017. URL: http://dx.doi.org/10.1093/brain/awx184, doi:10.1093/brain/awx184. This article has 126 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/brain/awx184)

[3. (Rhodes1997Association) Kenneth J. Rhodes, Brian W. Strassle, Michael M. Monaghan, Zewditu Bekele-Arcuri, Maria F. Matos, and James S. Trimmer. Association and colocalization of the kvβ1 and kvβ2 β-subunits with kv1 α-subunits in mammalian brain k+channel complexes. The Journal of Neuroscience, 17(21):8246–8258, November 1997. URL: http://dx.doi.org/10.1523/jneurosci.17-21-08246.1997, doi:10.1523/jneurosci.17-21-08246.1997. This article has 251 citations.](https://doi.org/10.1523/jneurosci.17-21-08246.1997)

[4. (Gu2014Physiological) Yuanzheng Gu and Chen Gu. Physiological and pathological functions of mechanosensitive ion channels. Molecular Neurobiology, 50(2):339–347, February 2014. URL: http://dx.doi.org/10.1007/s12035-014-8654-4, doi:10.1007/s12035-014-8654-4. This article has 75 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12035-014-8654-4)

[5. (Heitzmann2008Physiology) Dirk Heitzmann and Richard Warth. Physiology and pathophysiology of potassium channels in gastrointestinal epithelia. Physiological Reviews, 88(3):1119–1182, July 2008. URL: http://dx.doi.org/10.1152/physrev.00020.2007, doi:10.1152/physrev.00020.2007. This article has 163 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1152/physrev.00020.2007)

[6. (Corbett2016DominantKCNA2mutation) Mark A. Corbett, Susannah T. Bellows, Melody Li, Renée Carroll, Silvana Micallef, Gemma L. Carvill, Candace T. Myers, Katherine B. Howell, Snezana Maljevic, Holger Lerche, Elena V. Gazina, Heather C. Mefford, Melanie Bahlo, Samuel F. Berkovic, Steven Petrou, Ingrid E. Scheffer, and Jozef Gecz. Dominantkcna2mutation causes episodic ataxia and pharmacoresponsive epilepsy. Neurology, 87(19):1975–1984, November 2016. URL: http://dx.doi.org/10.1212/WNL.0000000000003309, doi:10.1212/wnl.0000000000003309. This article has 110 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1212/WNL.0000000000003309)

[7. (Niday2018Potassium) Zachary Niday and Anastasios V. Tzingounis. Potassium channel gain of function in epilepsy: an unresolved paradox. The Neuroscientist, 24(4):368–380, March 2018. URL: http://dx.doi.org/10.1177/1073858418763752, doi:10.1177/1073858418763752. This article has 108 citations.](https://doi.org/10.1177/1073858418763752)

[8. (Döring2021Refining) Jan H. Döring, Julian Schröter, Jerome Jüngling, Saskia Biskup, Kerstin A. Klotz, Thomas Bast, Tobias Dietel, G. Christoph Korenke, Sophie Christoph, Heiko Brennenstuhl, Guido Rubboli, Rikke S. Møller, Gaetan Lesca, Yves Chaix, Stefan Kölker, Georg F. Hoffmann, Johannes R. Lemke, and Steffen Syrbe. Refining genotypes and phenotypes in kcna2-related neurological disorders. International Journal of Molecular Sciences, 22(6):2824, March 2021. URL: http://dx.doi.org/10.3390/ijms22062824, doi:10.3390/ijms22062824. This article has 26 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22062824)

[9. (Imbrici2021A) Paola Imbrici, Elena Conte, Rikard Blunck, Fabrizia Stregapede, Antonella Liantonio, Michele Tosi, Maria Cristina D’Adamo, Annamaria De Luca, Vesna Brankovic, and Ginevra Zanni. A novel kcna2 variant in a patient with non-progressive congenital ataxia and epilepsy: functional characterization and sensitivity to 4-aminopyridine. International Journal of Molecular Sciences, 22(18):9913, September 2021. URL: http://dx.doi.org/10.3390/ijms22189913, doi:10.3390/ijms22189913. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms22189913)